Actavis plans name change to Allergan
Drugmaker Actavis is planning to change its name as it draws closer to finishing another big deal, the $66 billion purchase of Botox maker Allergan that it announced last fall.
Feb 18, 2015
0
2
Drugmaker Actavis is planning to change its name as it draws closer to finishing another big deal, the $66 billion purchase of Botox maker Allergan that it announced last fall.
Feb 18, 2015
0
2
A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.
Nov 20, 2014
0
0
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
Nov 17, 2014
0
0
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
Nov 4, 2014
0
0
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
Oct 27, 2014
0
0
Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.
Sep 25, 2014
0
0
Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.
Sep 24, 2014
0
0
Allergan and Pershing Square have agreed on at least one step toward settling a fight over the makeup of the Botox-maker's board.
Sep 16, 2014
0
0
Botox and eye-drug maker Allergan is suing a Canadian drugmaker and a hedge fund over their hostile takeover attempt, alleging insider trading and other fraud before their plan became public.
Aug 1, 2014
0
0
Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals.
Jul 21, 2014
0
0